The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic LeukaemiaAlessia Casolaro, Rachele Alzani, Josée Golay et al.|PLoS ONE|2013Cited by 34
Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disordersMaria Gabriella Brasca, Daniele Donati, Paola Gnocchi et al.|Bioorganic & Medicinal Chemistry|2015Cited by 20
Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.Elena Ardini, Arturo Galvani, Daniele Casero et al.|Molecular Cancer Therapeutics|2011Cited by 20
In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.Elena Ardini, Arturo Galvani, Maria Menichincheri et al.|Unknown|2011Cited by 11
Abstract 5163: Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myelomaClaudia Perrera, Barbara Valsasina, Maurizio Pulici et al.|Cancer Research|2017Cited by 1